FMA
CORT icon

FNY Managed Accounts’s Corcept Therapeutics CORT Stock Holding History

FNY Managed Accounts’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,980
Closed -$173K – 685
2017
Q3 		$173K Buy
+8,980
New +$134K 0.23% 68

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

FNY Managed Accounts's CORT Position: Q4 2017 in Review

FNY Managed Accounts sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 8,980 shares — an estimated $173K sold.

FNY Managed Accounts first reported a position in CORT in Q3 2017 and held it in 1 quarter. The position peaked at $173K in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

  • FNY Managed Accounts reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 8,980 Corcept Therapeutics shares in Q4 2017, an estimated $173K.
  • FNY Managed Accounts first reported a position in Corcept Therapeutics in Q3 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Corcept Therapeutics position peaked at $173K in Q3 2017.
  • 190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.